Identification of PRDX5 as A Target for The Treatment of Castration‐Resistant Prostate Cancer

Identification of PRDX5 as A Target for The Treatment of Castration‐Resistant Prostate Cancer

Abstract Treatment of castration‐resistant prostate cancer (CRPC) is a long‐standing clinical challenge. Traditionally, CRPC drugs work by either reducing dihydrotestosterone biosynthesis or blocking androgen receptor (AR) signaling. Here it is demonstrated that AR inhibitor treatment gives rise to...

Full description

Bibliographic Details
Main Authors: Rong Wang, Yuanyuan Mi, Jiang Ni, Yang Wang, Lingwen Ding, Xuebin Ran, Qiaoyang Sun, Soo Yong Tan, H Phillip Koeffler, Ninghan Feng, Yong Q Chen
Format: Article
Language:English
Published: Wiley 2024-03-01
Series:Advanced Science
Subjects:
castration‐resistant prostate cancer
drug‐tolerant persister
peroxiredoxin 5
polaprezinc
stachyose
Online Access:https://doi.org/10.1002/advs.202304939

Internet

https://doi.org/10.1002/advs.202304939

Similar Items